NasdaqHealth CareHealth Care EquipmentS&P 500Nasdaq-100
$82.38
-1.37 (-1.64%)
Close of Nov 06, 2026 · end-of-day data
GEHC 8-K filings, explained
Every material Form 8-K GE HealthCare has filed with the SEC since February 13, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
GE HealthCare said Taha Kass-Hout notified the company on November 4, 2026 that he will resign as Chief Science and Technology Officer. His last day will be December 31, 2026. The filing gives no successor name or reason for the departure.
Taha Kass-Hout will resign as Chief Science and Technology Officer.
He notified GE HealthCare on November 4, 2026.
His last day at the company will be December 31, 2026.
GE HealthCare reported third quarter 2026 revenue of $5.5 billion, up 7.2%, and net income attributable to the company of $615 million versus $446 million a year earlier. The company raised its full-year 2026 adjusted EPS guidance to $4.95 to $5.05, and also disclosed that Jeannette Bankes, President and CEO of Patient Care Solutions, will resign effective November 15, 2026, with Neal Sandy succeeding her on November 16.
Q3 2026 revenue of $5.5 billion, up 7.2% (organic growth 6.2%); diluted EPS of $1.36 versus $0.98; adjusted EPS of $1.34 versus $1.07
Full-year 2026 adjusted EPS guidance raised to $4.95 to $5.05, from $4.80 to $5.00; organic revenue growth now about 4.0%
Jeannette Bankes to resign as President and CEO, Patient Care Solutions, with last day November 15, 2026; Neal Sandy to become President and CEO on November 16, 2026
Company plans to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash, expected to close in the first half of 2027
GE HealthCare appointed Pascal Desroches, Senior Executive Vice President and CFO of AT&T, as a director effective January 4, 2027, and to its Audit Committee and Talent, Culture, and Compensation Committee. The filing says he plans to retire from AT&T on December 31, 2026, and that the appointment adds finance and governance experience to the board.
Pascal Desroches joins the GE HealthCare Board effective January 4, 2027.
He will serve on the Audit Committee and the Talent, Culture, and Compensation Committee.
Desroches has served as CFO of AT&T since 2021 and plans to retire from AT&T on December 31, 2026.
He will receive non-employee director compensation and enter into an indemnification agreement with the company.
GE HealthCare appointed William K. Grogan, currently executive vice president and CFO of Xylem Inc., as Chief Financial Officer effective September 14, 2026, succeeding interim CFO George Newcomb, who will remain Controller and Chief Accounting Officer. The filing sets out his pay package, including a $900,000 base salary, a 100% target bonus, and sign-on awards to offset compensation forfeited at Xylem, which matters to shareholders as it defines the company's new top finance executive and its compensation commitments.
Grogan, age 48, has been Xylem's EVP and CFO since October 2023 and was IDEX Corporation's CFO from January 2017 to September 2023.
Offer letter: $900,000 base salary, target annual bonus of 100% of salary, and a 2026 annual LTI award with a $3,300,000 target grant date value.
Sign-on payments include $550,000 in cash and a $4,000,000 RSU award, with cash repayment required if he resigns within two years.
Newcomb ceases as interim CFO on September 14, 2026, and continues as Controller and Chief Accounting Officer.
GE HealthCare reported second quarter 2026 revenue of $5.3 billion, up 5.7%, and net income attributable to the company of $561 million, up from $486 million a year earlier. Results were helped by $129 million of net income from IEEPA tariff refunds, and the company reaffirmed its full-year 2026 guidance, though its Patient Care Solutions segment declined and the company is reviewing strategic options for that business.
Diluted EPS was $1.24 versus $1.06, and adjusted EPS was $1.13 versus $1.06, with both measures benefiting from tariff refunds and a lower tax rate.
Adjusted EBIT margin was 14.2% versus 14.6%, down 40 basis points, and Patient Care Solutions revenue fell 13.3% to $675 million with a segment EBIT loss of $26 million.
Total orders rose 11.1% organically, with backlog of $23.9 billion at June 30, 2026.
The company repurchased 3.3 million shares for $200 million and declared a quarterly dividend of $0.035 per share, and it reaffirmed full-year adjusted EPS guidance of $4.80 to $5.00.
GE HealthCare said CFO Jay Saccaro will step down for a role outside the medical technology industry, with his last day on August 14, 2026, and Controller George Newcomb will serve as interim CFO. The company also reported preliminary second quarter 2026 results, with revenue up 5.7% year over year and adjusted EPS ahead of its prior expectation, and it reaffirmed full-year 2026 guidance.
Saccaro will leave as CFO; his last day is August 14, 2026, and the company has started a search for a permanent successor.
Controller and Chief Accounting Officer George Newcomb becomes interim CFO effective August 14, 2026, with no change to his compensation.
Preliminary Q2 2026 revenue was $5,295 million, up 5.7% year over year; organic revenue growth was 3.5%.
Adjusted EPS is expected to be ahead of prior expectation; full-year 2026 guidance was reaffirmed, and full Q2 results are due July 29, 2026.
GE HealthCare reported first quarter 2026 revenue of $5.1 billion, up 7.4%, but net income attributable to the company fell to $389 million from $564 million and diluted EPS fell to $0.85 from $1.23. The company cut its full-year 2026 Adjusted EPS guidance to $4.80 to $5.00 from $4.95 to $5.15, citing higher memory chip, oil and freight costs, so shareholders face lower expected profit this year even as sales grew.
Q1 2026 revenue of $5.1 billion, up 7.4%; organic revenue growth of 2.9%
Net income attributable to GE HealthCare of $389 million vs. $564 million; Adjusted EPS of $0.99 vs. $1.01
2026 Adjusted EPS guidance cut to $4.80 to $5.00 from $4.95 to $5.15; free cash flow guidance cut to about $1.6 billion from about $1.7 billion
Quarterly dividend declared at $0.035 per share; $100 million of stock repurchased in the quarter
GE HealthCare appointed Kevin A. Lobo, Chair and CEO of Stryker Corporation, as a director effective March 13, 2026, and named him to the Talent, Culture, and Compensation Committee. Directors Risa Lavizzo-Mourey and Tomislav Mihaljevic told the Board they will not stand for re-election at the 2026 Annual Meeting of Stockholders due to other commitments, and the filing says their decisions did not stem from any disagreement with the Company.
Kevin A. Lobo appointed director effective March 13, 2026; term expires at the 2026 Annual Meeting of Stockholders
Lobo also appointed to the Talent, Culture, and Compensation Committee, effective immediately
Risa Lavizzo-Mourey and Tomislav Mihaljevic will not stand for re-election at the 2026 Annual Meeting
Lobo is Chair and CEO of Stryker Corporation and will receive non-employee director compensation under the existing program
GE HealthCare entered into a new 364-day, $0.5 billion senior unsecured revolving credit agreement with JPMorgan Chase Bank, N.A. as administrative agent, replacing an identical-sized facility dated March 27, 2025, which was terminated without penalty on February 26, 2026. The filing describes a routine refinancing of a short-term credit line, and the filing does not state any amount drawn or any change in results.
New $0.5 billion 364-day revolving credit facility dated February 26, 2026, maturing February 25, 2027
Replaces the 2025 364-Day Revolving Credit Agreement of March 27, 2025, which was terminated without penalty on February 26, 2026
Pricing based on the Company's senior unsecured long-term debt ratings; includes customary covenants and change-of-control default
GE HealthCare reported fourth quarter and full year 2025 results on February 4, 2026, with revenue up in both periods. Fourth quarter diluted EPS fell to $1.29 from $1.57 as tariff expense weighed on profit, while full year diluted EPS rose to $4.55 from $4.34. The company also introduced 2026 guidance calling for adjusted EPS of $4.95 to $5.15.
Q4 2025 revenue of $5.7 billion, up 7.1%; organic revenue growth of 4.8%
Q4 diluted EPS of $1.29 versus $1.57; adjusted EPS of $1.44 versus $1.45
Full year 2025 revenue of $20.6 billion, up 4.8%; diluted EPS of $4.55 versus $4.34
2026 guidance: adjusted EPS of $4.95 to $5.15 and free cash flow of approximately $1.7 billion; $2.3 billion Intelerad acquisition expected to close in first half of 2026
On December 15, 2025, GE HealthCare issued $600 million of 4.150% senior notes due 2028 and $650 million of 4.950% senior notes due 2035. On December 12, 2025, it also agreed to a three-year, $750 million unsecured term loan with JPMorgan Chase Bank, N.A. as administrative agent. The company says it will use these proceeds and cash on hand to pay the purchase price for its previously announced acquisition of Intelerad Medical Systems, which adds new debt that shareholders should weigh against the deal.
$600 million 4.150% senior notes due December 15, 2028, and $650 million 4.950% senior notes due December 15, 2035, issued December 15, 2025
$750 million three-year unsecured term loan under a credit agreement dated December 12, 2025, with JPMorgan Chase Bank, N.A. as administrative agent; the loan will be made in a single borrowing on a future date
Proceeds, the term loan and cash on hand are intended to pay the purchase price for the Intelerad Medical Systems acquisition
The term loan agreement includes covenants limiting liens, fundamental change transactions, leverage and subsidiary debt, plus a change-of-control event of default
GE HealthCare reported third quarter 2025 revenue of $5.1 billion, up 6% from a year earlier, but adjusted earnings per share fell to $1.07 from $1.14 as tariffs weighed on profit. The company raised the lower end of its full-year 2025 adjusted EPS guidance to $4.51 from $4.43 and reaffirmed its other targets.
Revenue of $5.1 billion rose 6% reported and 4% organic year over year; total company orders grew 6% organically.
Net income attributable to GE HealthCare was $446 million versus $470 million; diluted EPS was $0.98 versus $1.02.
Adjusted EPS was $1.07 versus $1.14; the company said tariffs hurt margin and EPS, and would have exceeded prior year without them.
Full-year 2025 adjusted EPS guidance is $4.51 to $4.63, including about $0.45 of tariff impact; free cash flow for the quarter was $483 million versus $651 million.
GE HealthCare reported second quarter 2025 revenue of $5.0 billion, up 3% from a year earlier, and net income attributable to the company of $486 million versus $428 million. It raised its full-year 2025 adjusted EPS guidance to $4.43 to $4.63 from $3.90 to $4.10, and its free cash flow guidance to at least $1.4 billion from at least $1.2 billion. Adjusted EBIT margin fell to 14.6% from 15.3%, which the company attributed mainly to tariffs.
Q2 2025 revenue was $5.0 billion, up 3% reported and 2% organic year over year.
Diluted EPS was $1.06 versus $0.93; adjusted EPS was $1.06 versus $1.00.
2025 adjusted EPS guidance raised to $4.43 to $4.63 from $3.90 to $4.10, including about $0.45 of tariff impact.
Adjusted EBIT margin was 14.6% versus 15.3%, down 80 bps, impacted by tariffs.
GE HealthCare Technologies disclosed that director Lloyd W. Howell, Jr. resigned from its Board of Directors, effective immediately, with notice given on July 23, 2025. The company said the resignation was not due to any disagreement over its operations, policies, or practices.
Lloyd W. Howell, Jr. notified the company of his resignation on July 23, 2025
Resignation from the Board is effective immediately
Company states no disagreement on operations, policies, or practices led to the departure
GE HealthCare reported first quarter 2025 revenue of $4.8 billion, up 3%, and diluted EPS of $1.23 versus $0.81 a year earlier. The company also cut its full-year 2025 guidance, including adjusted EPS of $3.90 to $4.10 versus prior guidance of $4.61 to $4.75, and said the outlook includes about $0.85 of tariff impact. The Board also authorized a $1 billion share repurchase program with no expiration date.
Q1 2025 revenue $4.8 billion, up 3% reported and 4% organic; diluted EPS $1.23 versus $0.81; adjusted EPS $1.01 versus $0.90
2025 adjusted EPS guidance lowered to $3.90-$4.10 from $4.61-$4.75, including about $0.85 of tariff impact
Free cash flow guidance lowered to at least $1.2 billion from at least $1.75 billion; Q1 free cash flow was $98 million versus $274 million
Board authorized up to $1 billion in share repurchases with no expiration date
On March 27, 2025, GE HealthCare entered into two new unsecured revolving credit facilities with JPMorgan Chase Bank as administrative agent, totaling $3.5 billion in committed amounts. The new facilities replaced two earlier credit agreements, which were terminated without penalty on the same date. The filing describes a refinancing of existing credit capacity rather than new borrowing, and it discloses no drawn amounts.
New $3.0 billion senior unsecured revolving credit facility matures March 27, 2030
New $0.5 billion 364-day revolving credit facility matures March 26, 2026
Replaces a $1.0 billion facility from December 11, 2024 (Citibank) and a $2.5 billion facility from November 4, 2022 (Citibank), both terminated March 27, 2025
GE HealthCare reported fourth-quarter 2024 revenue of $5.3 billion, up 2% year over year, and diluted EPS of $1.57 versus $0.88 a year earlier. For full-year 2024, revenue was $19.7 billion, up 1%, and adjusted EPS was $4.49 versus $3.93. The company also introduced 2025 guidance calling for adjusted EPS of $4.61 to $4.75, which it says represents 3% to 6% growth.
Q4 2024 revenue was $5.3 billion, up 2%; net income attributable to GE HealthCare was $720 million versus $403 million
Q4 2024 adjusted EPS was $1.45 versus $1.18; full-year 2024 adjusted EPS was $4.49 versus $3.93
2025 guidance: organic revenue growth of 2% to 3%, adjusted EBIT margin of 16.7% to 16.8%, and free cash flow of at least $1.75 billion
Full-year 2024 free cash flow was $1.6 billion, down $161 million year over year
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every GE HealthCare filing is on SEC EDGAR ↗. 8-K briefs of other companies →